Williams-Beuren syndrome (WS) is a developmental disorder caused by a hemizygous microdeletion of approximately 1.4 MB at chromosomal location 7q11.23. The transcription map of the WS critical region is not yet complete. We have isolated and characterised a 3.4 kb gene, GTF3, which occupies about 140 kb of the deleted region. Northern blot analysis showed that the gene is expressed in skeletal muscle and heart, and RT-PCR analysis showed expression in a range of adult tissues with stronger expression in foetal tissues. Part of the conceptual GTF3 protein sequence is almost identical to a recently reported slow muscle-fibre enhancer binding protein MusTRD1, and shows significant homology to the 90 amino-acid putative helix-loop-helix repeat (HLH) domains of the transcription factor TFII-I (encoded for by the gene GTF2I). These genes may be members of a new family of transcription factors containing this HLH-like repeated motif. Both GTF3 and GTF2I map within the WS deleted region, with GTF2I being positioned distal to GTF3. GTF3 is deleted in patients with classic WS, but not in patients we have studied with partial deletions of the WS critical region who have only supravalvular aortic stenosis. A feature of WS is abnormal muscle fatiguability, and we suggest that haploinsufficiency of the GTF3 gene may be the cause of this.
Introduction
Williams syndrome (WS: MIM 194050) is a rare condition (1/20 000) with striking physical and behavioural features. 1 People with WS have an unusual pattern of abilities (Williams Syndrome Cognitive Profile, WSCP), which include relatively good verbal abilities but deficient visuo-spatial abilities, [2] [3] [4] [5] and characteristic personality traits. 6, 7 Physically, there is growth retardation, a dysmorphic face, heart abnormalities (typically supravalvular aortic stenosis, SVAS), and sometimes severe infantile hypercalcaemia and hyperacusis. 8 WS is caused by a chromosomal microdeletion at 7q11. 23 . 9 This chromosomal region is highly repetitive and the deletion arises from recombination between misaligned repeat sequences flanking the WS region.
The deletion breakpoints cluster within these repeat regions, so that most WS patients have similar deletions of approximately 1.4 Mb. 11 Intensive transcription mapping has allowed identification of a number of genes localised to the WS critical region. Elastin (ELN) was the first deleted gene identified 12 and studies of patients with deletions or point mutations confined to this gene showed that hemizygosity for ELN causes SVAS but not the other typical features of WS. 12 Other genes since identified are shown in Table 1 . [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] All these genes appear to be deleted in most WS patients. No phenotype has been clearly assigned to haploinsufficiency for any of them and some are deleted in patients ascertained through SVAS who do not have WS. 13 This suggests that other genes within the deleted region may be responsible for the main features of WS apart from SVAS.
In our efforts to build a complete transcription map of the WS critical region, we have identified and characterised a potential transcription factor gene, GTF3. MusTRD1, a recently described slow musclefibre enhancer binding protein, 23 appears to be a partial transcript of this gene. There is significant homology to the putative helix-loop-helix repeat domains identified in the transcription factor TFII-I 24 (encoded for by the gene GTF2-I 18 ). We have shown that GFT3 is deleted in patients with classic WS but not in SVAS patients with partial deletions within the critical region who lack other features of WS. We suggest that haploinsufficiency of GTF3 causes the muscle fatigue and lack of stamina seen in patients with WS.
Materials and Methods

GTF3 cDNA Isolation
A human 18-week foetal brain cDNA library (Gibco, Paisley, UK) was screened using the BAC clone 175E7 from within the WS deleted region. The DNA insert was isolated from the vector by Not1 digestion and separated by PFGE in 1% lowmelting TAE buffer with linear ramping of 5-15 s at a field intensity of 6 V/cm on a Bio-Rad Chef-DRIII PFGE apparatus. The inserts were sized against a low-size range marker (Bio-Rad, Herts, UK).
The DNA insert was then cut out of the gel and purified using a Geneclean resin. Hybridisation conditions were used according to the manufacturer's instructions and the repeats were competed out using placental DNA at a 100-fold excess. Stringent washing was used to avoid false positive signals. Isolated cDNA plasmid clones were miniprepped (Promega Wizard kit, Southampton, UK) and cycle sequenced using the Thermosequenase II sequencing kit (Amersham, Buckinghamshire, UK) and visualised on an ABI 373 fluorescent sequencer.
5' and 3' RACE This was carried out as described by
Frohman et al 25 using the following primers:
5'RACE: GAACGCGGAGTTCCAGCGGTCG
3'RACE: GCCGGTGCTGGTCCCTTATAAAC
Gene Expression Studies
A northern blot of poly(A) + RNA from various human tissues (Clontech, Hampshire, UK) was probed with the GTF3 cDNA clone and a -actin control, and hybridised according to the manufacturer's instructions.
RT-PCR Analysis
Total RNA (1 µg) from each RNA sample was reverse transcribed using a first-strand cDNA synthesis kit (Promega, Southampton, UK). Primers made from unique GTF3 sequence were used to PCR amplify the cDNA samples. PCR conditions used were: 50 ng of cDNA, 10 pmol of each primer and 0.5 U Taq polymerase (BCL, Cheshire, UK) used with the manufacturer's buffer, in a 20 µl reaction. PCR conditions were: 2 min denaturation at 94°C, followed by 30 cycles of 94°C 1 min, 60°C 1 min, 72°C 1 min, with a 5 min extension at 72°C. The integrity of the RNA was assessed by PCR analysis of the human -actin gene (330 bp product) using the same cycling conditions. Primer sequences:
GTF3 splice isoforms F: GCCCGAGCTGCTCACTGAGGGAGT GFT3 splice isoforms R: ATGATGACCATGCGGACATGCTC 
Fluorescence in situ Hybridisation
Metaphase spreads of chromosomes from patients were prepared from EBV transformed lymphoblastoid cell lines using standard techniques. FISH was carried out as described previously 13 using BAC probes containing the GTF3 gene. A cosmid mapping to chromosome 7 p was used to identify the chromosome 7 homologues and as an internal control.
Somatic Cell Hybrids
Hybrid cell lines were isolated after fusion of lymphoblastoid cells from the patients with mouse BW5147 cells as previously described.
14 The presence of a single chromosome 7 in all cell lines was verified by FISH analysis of interphase nuclei using a chromosome 7 specific centromeric probe (Oncor, Middlesex, UK) and on metaphase chromosomes using a human chromosome 7 specific paint (Cambio, Cambridge, UK). Hybrids containing normal and deleted chromosomes were distinguished by FISH (WSCR elastin probe, Oncor, Middlesex, UK), and microsatellite typing using D7S1870 with D7S653 as a control.
The preparation and analysis of hybrid cell lines from the WS and SVAS patients has been previously described. 13 
Deletion Mapping of Hybrids by PCR
Primers were designed for PCR analysis of somatic cell hybrids from the 5' and 3' GTF3 cDNA sequence. 50 ng of DNA, 10 pmol of each primer and 0.5 U Taq polymerase (BCL, Cheshire, UK) were used with the manufacturer's buffer, in a 20 µl reaction. PCR conditions were: 2 min denaturation at 94°C, followed by 30 cycles of 94°C 1 min, 60°C 1 min, 72°C 1 min, with a 5 min extension at 72°C.
Results
Isolation and Characterisation of the GTF3 Gene
A recombinant pCMV.SPORT plasmid containing a novel human gene was isolated by screening an 18-week human foetal brain cDNA library with BAC 175E7, which lies within the telomeric region of the WS microdeletion.
11
Three overlapping clones were obtained, consisting of partial transcripts of the same gene. The 5' and 3' termini were obtained by RACE extension and the nucleotide sequence of the gene was determined from both strands ( Figure 1) .
Searches in the EMBL database identified regions of homology in three BAC/PAC clones, RG228D17, DJ665P05 and DJ1186P10. Sequence comparisons between the cDNA clones and these genomic clones allowed some of the exon-intron boundaries to be determined. The rest were identified by sequencing directly from the BAC/PAC clones using cDNA specific primers. In this way we were able to define the genomic organisation of the gene, which we named GTF3 ( Figure 2 ).
The GTF3 cDNA is 3421 bp in size with a coding region of 2835 bp (starting from the first methionine residue). It is composed of 27 exons ranging in size from 26 bp to 311 bp. The sizes of the introns were estimated from the sequence of the genomic BAC/PAC clones. All the introns have the consensus splice donor and acceptor sequences.
Sequence analysis of all the cDNA clones isolated demonstrated the existence of two isoforms differing by an in-frame insertion of 15 aminoacids, produced by the use of two alternative acceptor splice sites in intron 18. This was confirmed by RT-PCR analysis ( Figure 5B ).
The 5' UTR is interrupted by a large intron of approximately 53880 bp which contains the microsatellite repeat, D7S2472, commonly used for deletion mapping in WS patients. The presumed ATG initiation codon is located in exon 2 of the gene, although computer analysis identified an in-frame CTG, 63 bp further upstream in the same exon, as a possible alternative start codon. This CTG lies in an optimal primary Kozak consensus sequence (A or G in position -3 and G in position + 4) and has a number of downstream stem-loop (hairpin) structures due to the GC-rich sequence, as predicted by a secondary structure programme (RNA Draw). Kozak 26 has shown the variable ability of mammalian ribosomes to initiate translation at non-AUG codons in cases where stemloop structures are formed downstream from the alternative initiator codon. Following protein analyses were carried out using the conventional methionine start site.
We estimate that the GTF3 gene spans a genomic distance of approximately 140 kb. PCR mapping using the clones in our contig of the WS critical region 11 shows that the gene lies in a 5' to 3' orientation from the centromere to the telomere and lies proximal to the 
Sequence Analysis and Homology with MusTRDI and TFII-I
BLAST analysis 27 of GTF3 (from the first ATG codon) with a non-redundant protein database showed that aminoacids 1 to 434 (out of 959 aminoacid residues) are A transcription factor involved in skeletal muscle gene M Tassabehji et al t identical to residues 1 to 434 (out of 458 amino-acid residues) of a recently submitted gene MusTRDI (human muscle TFII-I repeat domain containing protein 1), 23 except at two positions. There were sequence discrepancies G132S and V411G. Only the C-terminal 24 amino acid sequence of MusTRD1 does not align with GTF3.
The BLAST analysis also revealed significant homology to the family of transcription factors TFII-I (also known as SPIN). The major regions of homology involve a repeated amino-acid motif previously described in TFII-I 24 ( Figure 3) . Sequence alignment between TFII-I and GTF3 shows that 20/79 aminoacids possess a match in all the repeats in both genes, with no more than one residue variation; and 31/79 residues possess the same amino-acids in at least three repeats in one gene and at least two repeats in the other. Further homology is evident on inspection of Figure 3B . Significant homology (34/66 identity, 17 conservative changes) was also detected at the N-terminus between TFII-I residues 21-86 and GTF3 residues 29-94 ( Figure 3A ). This sequence was not repeated elsewhere in the coding sequence of either gene, and did not show homology to any motifs in the PROSITE database. 28 The amino acid sequence that is variable between the two GTF3 isoforms did not show significant homology to TFII-I and lay outside the conserved repeated motifs. ). They appear to be localised within the nucleus, based on Euclid distances between 11 normalised methods for determining localisation to different compartments of the cell (74% probability 30 ). A run of 12 serine residues 
Predicted Properties of GTF3 Protein
Both GTF3 isoforms are predicted to be soluble proteins
between TFII-I residues 21-86 and GTF3 residues 29-94 with 34/66 identity and 17 conservative changes. 3B Alignment of the repeat domains in TFII-I and GTF3. Bases in red: conserved; Bases in blue: semi-conserved. 20/79 amino acids possess a match in all the repeats in both genes (no more than one residue variation); 31/79 residues possess the same amino acids in at least three repeats in one gene and at least two repeats in the other.
A transcription factor involved in skeletal muscle gene t occurs at the C-terminus of the protein. Multi-serine runs appear to be a feature of many soluble proteins. Many of these are nuclear (eg Humhoxy1, a zinc finger DNA-binding protein AC:D45132), and some bind DNA and RNA. There does not appear to be any other relationship between GTF3 protein and the proteins in the database with multi-serine runs. PSORT II, PRO-SITE, BLOCKS, 31 and PRINTS 32 did not detect any strong sequence homology to known DNA or RNA binding motifs.
Protein secondary structure predictions (GORB-TURN 33, 34 ) suggest a highly helical structure in the N-terminal half of the sequence, whilst the C-terminal half appears to be a mix of helix and beta-sheet.
Analysis of Expression Pattern
Northern blot analysis using an almost complete cDNA probe (exon 2 to the 3'UTR) showed expression mainly in skeletal muscle and the heart, but the presence of stronger -actin control bands in these tissues suggests that the blot used is unequally loaded ( Figure 4A ). Under the stringent hybridisation conditions employed to avoid cross-hybridisation with GTF2-I, we were able to identify one main mRNA band of approximately 3.5 kb, and a weak band of approximately 5 kb. Our cDNA construct for GTF3 represents the 3.5 kb transcript, and the larger transcript may be a larger isoform or another gene with regions of homology.
RT-PCR analysis of a number of human adult and foetal tissues was carried out to detect low level expression of GTF3. Primers used for this analysis were designed in the unique regions of the gene to avoid PCR amplification of GTF2-I. The levels of GTF3 expression were estimated by comparison with an internal -actin control. GTF3 is highly expressed in all the foetal tissues tested, with lower levels of expression in the adult tissues ( Figure 4B) . Of the adult tissue tested, skeletal muscle, bone, a fibroblast cell line and an osteoblast-like bone cell line showed significantly higher GTF3 expression. Primers designed to amplify the individual isoforms of GTF3 showed that they are both expressed in all the tissues tested.
FISH Analysis of GTF3 in WS Patients
FISH analyses using a clone containing the GTF3 gene were carried out on five patients with classic WS (MB, DB, MC, GU, KE) and on three patients with SVAS only, who have partial deletions of the WS critical region (TM, CS and HG, previously described 11, 13 ). One copy of GTF3 was deleted in all of the WS patients, but not in any of the three SVAS patients, showing that their partial deletions did not extend as far as GTF3 (data not shown). There did not appear to be multiple copies of GTF3 on chromosome 7, and no signals were detected on any other chromosome.
GTF3 Deletion Analysis in WS Patients by Somatic Hybrid PCR
Because partially deleted genes can give detectable FISH signals, somatic cell hybrid lines were made from cells of the WS and SVAS patients to allow their deletion breakpoints to be more finely mapped. The normal and deleted copies of chromosome 7 were segregated, and stable cell lines established. Hybrids containing the deleted chromosome 7 from each patient were tested for the presence of GTF3 by PCR using primers designed from the 5' and 3' regions of the gene. A non-deleted marker was included as a positive control in the PCR reaction. Mouse DNA was also A transcription factor involved in skeletal muscle gene M Tassabehji et al t included as a control to show that the PCR amplification products were human specific. The results (Figure 5) show that the entire GTF3 gene is deleted in each WS patient but is not deleted in the three SVAS patients.
Discussion
We have isolated a single copy gene, named GTF3, mapping within the WS critical region, which is deleted in patients with WS but not in three patients who have smaller deletions and have no features of WS apart from supravalvular aortic stenosis. Structural analysis of GTF3 suggests that it may encode a transcription factor. The putative GTF3 protein is predicted to be soluble and localised to the nucleus, and shows homology to the transcription factor, TFII-I. Since submitting this manuscript, the gene WBSCR11 mapping to the WS critical region has been published 35 and sequence comparisons with GTF3 shows that there are some sequence and genomic organisation discrepancies, but the two genes have significant identity. Northern blot analysis of WBSCR11 shows transcripts of 1.8, 2 and 5 kb, in contrast to our main GTF3 transcript of 3.4 kb.
The homology to TFII-I involves two parts of the sequence. At the N-terminus there is strong homology over a 66 aminoacid run that does not correspond to any recognised motif in the databases. A second region of homology is to a 90-aminoacid potential helix-loophelix repeat motif, present in six copies in TFII-I and five in GTF3. TFII-I is reported to bind both proteins and DNA. DNA targets include Inr, Inr-like (SIE, SRE) and E-box elements, whilst the proteins include serum-response factor (a MADS box family transcription factor), Phox (a homeodomain protein) and USF1 (a bHLH protein). 36, 37 It is thought that the six potential HLH, repeat domains of TFII-I are important for its role as a co-ordinator of diverse cell signaling responses and the basal transcription machinery. 24 The conservation of such domains in GTF3 suggests that these genes belong to a new family of transcription factors which may play similar roles in vivo.
A recently reported gene, MusTRDI 23 is predicted to encode a protein identical, except at two positions, to aminoacids 24-455 of GTF3. The predicted MusTRD1 protein has a 21-aminoacid C-terminus that differs from the 510 aminoacids of the GTF3 C-terminus. Inspection of the MusTRD1 cDNA sequence shows the GTF3 downstream sequence is present, with a few minor discrepancies, but is interpreted as a 3' untranslated region. PCR did not amplify any sequence having the stop codon as reported for MusTRD1, and our FISH analysis confirmed that GTF3 is present in only a single copy in the genome. We conclude that MusTRD1 is GTF3, and that this gene encodes a protein with isoforms of 965 or 980 aminoacids.
MusTRD1 was identified by O'Mahoney et al 23 as a protein that binds to an enhancer involved in the regulation of skeletal muscle gene expression. They identified the sequence elements (E-box, MEF2, USE B1 and USE C1) of the human troponin I slow upstream enhancer (USE) that bind muscle nuclear proteins. They showed that the TnIs USE B1 sequence element appears to be essential for high-level expression in slow-twitch muscles, and cloned MusTRD1 as a gene encoding a 51 kDa USE B1 binding protein that is expressed predominantly in adult skeletal muscle. No chromosomal location was assigned. Our data on the expression profile of GTF3 show that it too is highly expressed in adult skeletal muscle, fibroblasts and bone, but foetal expression was much more pronounced and was seen at similar levels in all the tissues tested.
Skeletal muscle commitment, differentiation and maturation are largely controlled by genes encoding channels, receptors, metabolic enzymes and musclespecific contractile proteins, 38, 39 but not much is known about the regulatory elements that restrict transcription of genes encoding contractile proteins specifically to either slow or fast-twitch skeletal muscles. Troponin I (TnI), a member of the troponin complex that regulates muscle contraction in response to calcium flux, comprises three isoforms, fast (TnIf), slow (TnIs) and cardiac (TnIc). These isoforms are differentially regulated during skeletal muscle development. Most skeletal muscles contain a mixture of fibres with different characteristics, and their slow-twitch units are well known to possess properties suitable for postural tasks: they are highly fatigue-resistant, well equipped for oxidative metabolism, and their slowness makes them energetically cheap in (semi-)isometric contractions.
WS patients are reported to lack stamina 38 (KM, clinical observations 1999). Routine manual tasks considered suitable for people with learning difficulties, such as stacking shelves, packing or assembly-line work, are unsuitable for many patients with WS, partly because of their visuomotor difficulties, but also because of a lack of stamina and a tendency to tire easily. 40 Many young and old WS patients appear to suffer from muscle problems, ranging from slight aches like cramp, to noticeable pain from walking long distances (UK WS Foundation committee, personal communication 1999). Voit et al 41 have described myopathy in infancy in WS patients with clinical manifestations including walking delay, joint contractures and increased exhaustion on exertion. If the skeletal muscles of WS patients contained fewer slowtwitch fibres, they might be expected to tire more easily. There is evidence to suggest that a decrease in the proportion of fatigue-resistant slow fibres in skeletal muscle affects stamina. 42 In patients with chronic obstructive pulmonary disease the scarce oxygen availability and/or the inactivity and physical deconditioning are thought to cause fibre transformation, with an increase in the proportion of the fast fatiguable fibres that are responsible for lactate production and fatigue at low work rates. Investigations into the fibre composition in skeletal muscle biopsies from WS patients, as well as stamina tests, would be required to determine if this is also the case in Williams syndrome.
Both TFII-I and GTF3 appear to share similar properties and may play similar roles in regulating transcription of a number of genes. They map next to each other within the WS critical region, just outside the tandemly repeated region. We have previously shown 11 that GTF2I (TFII-I) is also deleted in patients with Williams syndrome. Transcription factors are often dosage-sensitive, and haploinsufficiency for transcription factors is a cause of a growing list of developmental defects, such as Waardenburg syndrome Types I and II and aniridia. Although GTF3 appears to be involved in controlling expression of a muscle gene, and shows significant expression in adult skeletal muscle, it is more highly and more widely expressed in fetal than in adult tissues. GTF3 occupies 10% of the entire WS critical region, and studies of rare patients with partial deletions suggests that this part of the critical region is important for determining the WS phenotype. 13, 43 GTF3 and/or TFII-I must be strong candidates for the critical WS genes.
